Description
Taurochenodeoxycholic acid (TCDCA) is a taurine-conjugated form of the primary bile acid chenodeoxycholic acid (CDCA; ). Serum levels of TCDCA increase approximately 5-fold in within two hours and begin to decrease within four hours during an oral lipid tolerance test in humans. Serum levels of TCDCA are increased in patients with liver cirrhosis and may serve as a marker of disease progression.
Chemical Properties
Solid
Uses
Labeled Taurochenodeoxycholic Acid, intended for use as an internal standard for the quantification of Taurochenodeoxycholic Acid by GC- or LC-mass spectrometry.
Uses
Taurochenodeoxycholic Acid Sodium Salt is a bile acid conjugate and metabolite Taurolithocholic Acid (T009100) with antiinflammatory activity. Taurochenodeoxycholic Acid has been shown to inhibit hepatocyte apoptosis through suppression of Bid translocation to mitochondria.
General Description
An ionic detergent used for solubilizing lipids and proteins.
in vivo
Taurochenodeoxycholic acid (12-Deoxycholyltaurine; TCDCA; 0.05, 0.1g/kg) sodium decreases the pulmonary coefficient in the model mice and reduces the pathological damages on their lungs; it can decrease the expression levels of TNF-α and TIMP-2 in pulmonary tissues in the pulmonary fibrosis mice and has no significant effects on MMP2[2].
Taurochenodeoxycholic acid sodium significantly normalizes the clinical inflammatory parameters, prevented indomethacin-induced increases in the biliary contents of secondary bile acids and hydrophobicity index, and tended to attenuate the intestinal inflammation[3].
Taurochenodeoxycholic acid sodium significantly suppresses paw swelling and polyarthritis index, increases the loss body weight and index of thymus and spleen, and amends radiologic changes in AA rats. The overproduction and mRNA expression of TNF-α, IL-1β and IL-6 are remarkably suppressed in serum and synovium tissue of all TCDCA-treated rats[4].
IC 50
Microbial Metabolite; Human Endogenous Metabolite
References
[1] HOFMANN A F. The continuing importance of bile acids in liver and intestinal disease.[J]. Archives of internal medicine, 1999, 159 22: 2647-2658. DOI:
10.1001/archinte.159.22.2647[2] A. SCHMID. Bile Acid Metabolome after an Oral Lipid Tolerance Test by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)[J]. PLoS ONE, 2016, 11 1. DOI:
10.1371/journal.pone.0148869[3] XIAONING WANG. Serum Bile Acids Are Associated with Pathological Progression of Hepatitis B-Induced Cirrhosis[J]. Journal of Proteome Research, 2015, 15 4: 1126-1134. DOI:
10.1021/acs.jproteome.5b00217
